Bruker raises FY24 EPS view to $2.79-$2.84, from $2.71-$2.76, consensus $2.71

Bruker’s FY 2024 updated guidance now includes the expected benefits of the Chemspeed acquisition closed in Q1 2024, and of the ELITech acquisition, which closed on April 30… Our updated FY 2024 guidance does not include the pending, EPS-dilutive NanoString acquisition, announced by Bruker on April 22 and expected to close in Q2-24. Bruker now expects FY 2024 revenues of $3.29 to $3.35 B, consenus $3.28B,up $60M from our prior guidance of $3.23 to $3.29B. Bruker’s updated FY 2024 revenue guidance implies 11% to 13% year-over-year reported revenue growth, up from our prior guidance of 9% to 11%, and including yoy contributions from: Organic revenue growth of 5% to 7%, no change from prior guidance…